UAB - Center for Clinical and Translational Science

• Of age ≥18 years or older. - Having a diagnosis of MM; newly diagnosed or relapsed/refractory disease - Undergoing systemic treatment through the UAB MM Clinic Pathway - Able to provide informed consent to be included in the intervention - MM patients in a prior/concurrent (non-pyscho/educational intervention), MM study will be eligible to participate - Have either SMS texting or email access to receive encouragement messages

Patients will be ineligible for the program if they are: - Being treated by end-of-life or comfort care measures only - MM patients not treated through the UAB MM Clinic Pathway. - MM patients not requiring systemic therapy. - Patients with a diagnosis of MGUS or SMM. - Have a history of other malignancy within the past [3 or 5] years with the exception of: - Malignancies treated with curative intent and with no known active disease present for ≥ 3 (or 5) years before enrollment and felt to be at low risk for recurrence by the treating physician - Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease - Adequately treated cervical carcinoma in situ without evidence of disease - Adequately treated breast ductal carcinoma in situ without evidence of disease - Prostatic intraepithelial neoplasia without evidence of prostate cancer - Adequately treated urothelial papillary noninvasive carcinoma or carcinoma in situ - Are enrolled in a prior/concurrent MM psycho-educational study Other Exclusions: - Patients who do not have either SMS texting or email access to receive encouragement messaging will be excluded - History or evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the investigator or Amgen physician, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion.